Cancer Management and Research · 2020 · 24 citations · 29 references
MedicineOncologySurgeryHematologic OncologySurgical OncologySurvival AnalysisCancer MortalityEsophageal CancerMalignant NeoplasmsNeoadjuvant ChemotherapyNeoadjuvant TherapySquamous Cell CarcinomaConcordance IndexCox RegressionEastern Cooperative Oncology Group Performance StatusNeoadjuvant ChemoradiationNeoadjuvant ChemoradiotherapyOncologic Outcomes AssessmentOverall MortalityPrognostic Marker Evaluation
PURPOSE: Our purpose was to evaluate the association between hematologic markers and mortality and adverse events in patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (nCRT). PATIENTS AND METHODS: A total of 311 patients with ESCC treated with nCRT from 2012 to 2014 were enrolled retrospectively. The Kaplan-Meier method with a Log rank test was used to calculate five-year overall survival (OS). Receiver operating characteristic (ROC) curves were plotted to determine the cut-off values for hematologic markers. Multivariate analysis was performed using Cox regression analysis model. Model performance was evaluated by predicted nomogram, concordance index (C-index) and calibration curve. RESULTS: Median follow-up was 22 months. High pretreatment platelet to lymphocyte ratio (PLR, p = 0.047) and systemic immune-inflammation index (SII, p = 0.027) were significantly associated with pathologic complete response (pCR). In multivariate analysis, smoking history, Eastern Cooperative Oncology Group (ECOG) performance status, invasion depth, lymph node metastasis, PLR, and SII were independent factors to predict five-year OS. Multivariate analysis showed a lower neutrophil to lymphocyte ratio (NLR) at baseline (p = 0.007) was significantly associated with development of grade ≥3 hematologic toxicity, and none of inflammatory biomarkers could predict grade ≥3 non-hematologic toxicity or radiation pneumonitis (RP). CONCLUSION: SII and PLR were independent indicators to predict prognosis in patients with ESCC treated with nCRT, and a lower NLR at baseline was an independent indicator to predict grade ≥3 hematologic toxicity.
29
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Global cancer statistics, 2012
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text
Anil K. Rustgi, Hashem B. El‐Serag · New England Journal of Medicine · 2014 · 1.3K citations
Hong Yang, Hui Liu, Yuping Chen et al. · Journal of Clinical Oncology · 2018 · 978 citations · Full text